{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T14:36:56Z","timestamp":1778596616680,"version":"3.51.4"},"reference-count":15,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"11","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,11]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:p>Fluoroquinolones, such as ciprofloxacin and levofloxacin, are broad-spectrum antibacterial agents that have historically been widely used for urinary tract infections, pneumonia, and intra-abdominal infections but are associated with several serious adverse reactions, including tendinopathy and tendon rupture, peripheral neuropathy, and aortic aneurysm. These drugs should not be used for uncomplicated infections unless no other antimicrobial treatment is feasible. This article describes a patient who experienced life-altering disability from a fluoroquinolone, reviews the adverse reactions of this drug class, and discusses recommended treatment for acute uncomplicated cystitis and asymptomatic bacteriuria.<\/jats:p>","DOI":"10.1097\/01.jaa.0000873776.37967.9b","type":"journal-article","created":{"date-parts":[[2022,10,25]],"date-time":"2022-10-25T16:02:33Z","timestamp":1666713753000},"page":"33-36","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":4,"title":["A preventable, life-altering case of fluoroquinolone-associated tendonitis"],"prefix":"10.1097","volume":"35","author":[{"given":"Anne","family":"Wildermuth","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Megan","family":"Holmes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20250606","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2017\/8023935","article-title":"Treatment of the fluoroquinolone-associated disability: the pathobiochemical implications","volume":"2017","author":"Michalak","year":"2017","journal-title":"Oxid Med Cell Longev"},{"issue":"5","key":"R2-20250606","doi-asserted-by":"crossref","first-page":"161","DOI":"10.18773\/austprescr.2021.035","article-title":"Fluoroquinolone antibiotics and adverse events","volume":"44","author":"Baggio","year":"2021","journal-title":"Austr Prescr"},{"issue":"6","key":"R5-20250606","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1002\/phar.1761","article-title":"Fluoroquinolone-associated tendinopathy: does levofloxacin pose the greatest risk","volume":"36","author":"Bidell","year":"2016","journal-title":"Pharmacotherapy"},{"issue":"10","key":"R6-20250606","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1007\/s00228-019-02713-1","article-title":"Fluoroquinolones and the risk of tendon injury: a systematic review and meta-analysis","volume":"75","author":"Alves","year":"2019","journal-title":"Eur J Clin Pharmacol"},{"issue":"11","key":"R7-20250606","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1517\/14740338.2015.1085968","article-title":"Fluoroquinolone-associated tendon-rupture: a summary of reports in the Food and Drug Administration's adverse event reporting system","volume":"14","author":"Arabyat","year":"2015","journal-title":"Expert Opin Drug Saf"},{"issue":"6","key":"R8-20250606","doi-asserted-by":"crossref","first-page":"465","DOI":"10.2165\/11587280-000000000-00000","article-title":"Quinolones: review of psychiatric and neurological adverse reactions","volume":"34","author":"Tom\u00e9","year":"2011","journal-title":"Drug Saf"},{"issue":"3","key":"R9-20250606","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.psym.2017.11.001","article-title":"Fluoroquinolone-related neuropsychiatric events in hospitalized veterans","volume":"59","author":"Sellick","year":"2018","journal-title":"Psychosomatics"},{"key":"R10-20250606","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2015-209821","article-title":"Fluoroquinolone-induced serious, persistent, multisymptom adverse effects","volume":"2015","author":"Golomb","year":"2015","journal-title":"BMJ Case Rep"},{"issue":"14","key":"R11-20250606","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1212\/WNL.0000000000000846","article-title":"Oral fluoroquinolone use and risk of peripheral neuropathy: a pharmacoepidemiologic study","volume":"83","author":"Etminan","year":"2014","journal-title":"Neurology"},{"issue":"2","key":"R12-20250606","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1159\/000334441","article-title":"QT prolongation and torsade de pointes induced by fluoroquinolones: infrequent side effects from commonly used medications","volume":"120","author":"Briasoulis","year":"2011","journal-title":"Cardiology"},{"issue":"10","key":"R13-20250606","doi-asserted-by":"crossref","first-page":"839","DOI":"10.2165\/11593110-000000000-00000","article-title":"Fluoroquinolone-associated myasthenia gravis exacerbation: evaluation of postmarketing reports from the US FDA adverse event reporting system and a literature review","volume":"34","author":"Jones","year":"2011","journal-title":"Drug Saf"},{"key":"R14-20250606","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1186\/s12879-015-1282-4","article-title":"Ciprofloxacin resistance in community- and hospital-acquired Escherichia coli urinary tract infections: a systematic review and meta-analysis of observational studies","volume":"15","author":"Fasugba","year":"2015","journal-title":"BMC Infect Dis"},{"issue":"10","key":"R15-20250606","doi-asserted-by":"crossref","first-page":"e83","DOI":"10.1093\/cid\/ciy1121","article-title":"Clinical practice guideline for the management of asymptomatic bacteriuria: 2019 update by the Infectious Diseases Society of America","volume":"68","author":"Nicolle","year":"2019","journal-title":"Clin Infect Dis"},{"issue":"5","key":"R16-20250606","doi-asserted-by":"crossref","first-page":"e103","DOI":"10.1093\/cid\/ciq257","article-title":"International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: a 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases","volume":"52","author":"Gupta","year":"2011","journal-title":"Clin Infect Dis"},{"issue":"1","key":"R17-20250606","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1093\/cid\/ciy035","article-title":"Opportunities to improve fluoroquinolone prescribing in the United States for adult ambulatory care visits","volume":"67","author":"Kabbani","year":"2018","journal-title":"Clin Infect Dis"}],"container-title":["JAAPA"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/01.JAA.0000873776.37967.9b","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,6]],"date-time":"2025-06-06T14:00:59Z","timestamp":1749218459000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/01.JAA.0000873776.37967.9b"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11]]},"references-count":15,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.1097\/01.jaa.0000873776.37967.9b","relation":{},"ISSN":["1547-1896"],"issn-type":[{"value":"1547-1896","type":"print"}],"subject":[],"published":{"date-parts":[[2022,11]]}}}